Dubai, United Arab Emirates, (AETOSWire): The vaccination marathon of the world’s population continues in 2021. Stocks of companies producing Covid-19 vaccines do not experience their all-time highs; they are in the same position as other sectors on financial markets. However, from the long-term perspective, production problems are expected to be resolved and ordered volumes are supposed to multiply their current values.
The use of the vaccine developed by AstraZeneca in cooperation with the University of Oxford is being approved by a growing number of regulatory bodies, which prepares the ground for its general use, namely in the developing countries.
AstraZeneca’s stocks are now traded at approximately the same level as in prior year and WHO’s approval of the vaccine may have a strong impact on the expansion of its use in other countries. Additionally, the company’s commitment not to profit from the sale of the COVID-19 vaccine may shuffle the cards with respect to its competitors.
AstraZeneca’s vaccine is sold for the lowest price among the currently available vaccines. According to the Belgian health minister, the price is EUR 1.80 (USD 2.20) per dose in the European Union compared to EUR 18 for a dose from Moderna and EUR 12 for Pfizer’s vaccine.
Pfizer, as the largest pharmaceutical company in the US, increased its year-on-year net profit by more than 76% in fourth quarter, representing nearly USD 600 million. This year, the company expects sales of about USD 15 million arising from the vaccine distribution. The company plans to supply approximately 2 million vaccines this year. Good news for the company came from Japan, where the Japanese Ministry of Health announced on Sunday that Pfizer’s Covid-19 vaccine had been officially approved. For the past few weeks, Pfizer stock trading has been consolidated with the price keeping close to USD 34.60 of 29 October 2020.
Moderna moves up its expected supplies of 300 million doses of COVID-19 vaccine to the end of July. On Tuesday (16 February 2021), the firm updated information on the supplies of its COVID-19 vaccine, expecting to supply 100 million doses to the US Government by the end of March.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
